Table 1

Baseline characteristics of patients with advanced-stage NLPHL and matched controls with advanced-stage CHL

CharacteristicNLPHL (n = 42)CHL (n = 84)*
No.%No.%
Follow-up, years     
 Median 11.3 10.7 
 Range 1.9-35.5 1.6-26.3 
Male sex 30 71 58 69 
Age, years     
 Median 37 37 
 Range 12-75 12-78 
 ≥45 17 40.5 31 37 
Stage     
 II 2 5 4 5 
 III 37 90 76 90 
 IV 2 5 4 5 
PS ≥2 4 9.5 8 9.5 
B symptoms 9 21 18 21 
Extranodal disease 2 5 8 9.5 
Spleen involvement 14 33 33 39 
Bulky mass ≥10 cm 0  0  
Mass ≥5 cm 13 31 38 45 
IPS ≥4 0  5 6 
Elevated LDH 3 7 16 19 
Treatment     
 ABVD-(like) chemotherapy 36 86 74 88 
 MOPP ± radiation 4 9.5 6 7 
 Radiation alone 2 5 4 5 
CharacteristicNLPHL (n = 42)CHL (n = 84)*
No.%No.%
Follow-up, years     
 Median 11.3 10.7 
 Range 1.9-35.5 1.6-26.3 
Male sex 30 71 58 69 
Age, years     
 Median 37 37 
 Range 12-75 12-78 
 ≥45 17 40.5 31 37 
Stage     
 II 2 5 4 5 
 III 37 90 76 90 
 IV 2 5 4 5 
PS ≥2 4 9.5 8 9.5 
B symptoms 9 21 18 21 
Extranodal disease 2 5 8 9.5 
Spleen involvement 14 33 33 39 
Bulky mass ≥10 cm 0  0  
Mass ≥5 cm 13 31 38 45 
IPS ≥4 0  5 6 
Elevated LDH 3 7 16 19 
Treatment     
 ABVD-(like) chemotherapy 36 86 74 88 
 MOPP ± radiation 4 9.5 6 7 
 Radiation alone 2 5 4 5 

There were missing values for mass size: NLPHL n = 3, CHL n = 4; spleen involvement: NLPHL n = 1; PS: NLPHL n = 1, CHL n = 2; elevated LDH: NLPHL n = 7, CHL n = 18; IPS score: NLPHL n = 5; CHL n = 11.

IPS, International Prognostic Score; LDH, lactate dehydrogenase.

*

Matching was performed for 42 NLPHL patients.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal